Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
26 hedge funds and large institutions have $12.4M invested in Cymabay Therapeutics in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 7 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
2% more capital invested
Capital invested by funds: $12.1M → $12.4M (+$298K)
13% less funds holding
Funds holding: 30 → 26 (-4)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$130K |
| 2 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$53.8K |
| 3 |
Renaissance Technologies
New York
|
+$35.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$33.3K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$33.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.62M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.14M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$323K |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$117K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$91K |
CBAY Hedge Fund Activity: Q2 2016 in Review
26 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2016, worth a combined $12.4M — up 2.5% from $12.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CBAY and 4 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $130K. The largest seller was Adage Capital Partners, cutting an estimated $1.62M.
- 26 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2016, down from 30 in Q1 2016.
- Funds reported $12.4M of Cymabay Therapeutics stock for Q2 2016, up 2.5% quarter-over-quarter.
- 4 funds opened new Cymabay Therapeutics positions in Q2 2016 and 7 closed out, a net change of -3 holders.
- The largest Cymabay Therapeutics buyer in Q2 2016 was Vanguard Group, an estimated $130K added.
- The largest Cymabay Therapeutics seller in Q2 2016 was Adage Capital Partners, an estimated $1.62M sold.
Based on aggregated 13F filings for Q2 2016.